Beta Drugs Limited Financial Ratios
BETA · Healthcare · Current price ₹1,790
P/E ratio
43.7x
P/B ratio
9.4x
ROE
16.9%
ROCE
17.8%
Debt / Equity
0.60
Dividend yield
0.0%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 43.7x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 9.4x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 16.9% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 17.8% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.60 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Beta Drugs Limited's latest numbers.
Beta Drugs Limited profitability
Beta Drugs Limited generates a return on equity of 16.9% and a return on capital employed of 17.8%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.60 and a P/E of 43.7x, Beta Drugs Limited is moderately leveraged. Our overall business-quality score for the company is 4.8 / 10.
Understand the ratios
More on Beta Drugs Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.